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Abstract: 
Stahl, Joshua (M.S., Chemistry, Department of Chemistry and Biochemistry) 
Small Molecule perturbation of the TLR4/MD-2 Interaction 
Thesis directed by Professor Hubert Yin 
 Opioid-induced glial cell activation has accumulated great interest over the past several 
years. Recent evidence suggests that glia are activated by opioids and that the activation of glial 
cells is linked to suppression in analgesia, leading to the development of opioid tolerance and 
dependence. Current study shows that opioid-induced glial activation is regulated by Toll-Like 
receptor-4(TLR4), a membrane spanning receptor that functions in complex with Myeloid 
differentiation factor-2 (MD-2). Interestingly TLR4 receptors are solely expressed by glia within 
the central nervous system (CNS), suggesting development of small molecules to improve 
opioid-based pain management therapies through the inhibition of the TLR4/MD-2 interaction 
in glial cells within the CNS. Initially the high-resolution crystal structure of the TLR4 
extracellular domain (2z62) was screened against an ENAMINE collection (a library of over 
700,000 compounds) in an ADMET in silico screen. This led to the identification of a handful of 
potential lead compounds. Initially every compound was tested through the use of a secreted 
alkaline phosphatase (SEAP) assay to measure TLR4 activation inhibition. Upon screening the 
hits, two leads were indentified for further testing, compounds 2126 and 4019. Both 
compounds were subject to further testing using a variety of cell and biophysical assays, 
including RAW nitric oxide production, Co-Immunoprecipitation, TLR-specificity assays, and Glial 
IL-1β production via enzyme linked immunosorbent assays done in conjunction with animal 
Page iv 
testing performed by Dr. Linda Watkins.  These studies have allowed us to shed light on the 
action of our small molecules leads and their analogs both in vitro and in vivo. Although further 
study is needed, these small molecules provide an exciting avenue for developing drug-like 
therapeutics to enhance opioid analgesia while minimizing opioid dependence and tolerance.
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Introduction/Background: 
 In the early 1980’s Nusslein-Valhard used the German word Toll to describe a gene they 
discovered in a genetic screen of Drosophila. Although there is no direct translation for Toll it 
nearly means fantastic or amazing (1).  The Toll sequence was found in 1988 and revealed a 
tripartite structure containing an N-terminal region with tandem arrays of short leucine rich 
repeats, a sequence to form a Transmembrane helix, and a C-terminal domain (1, 2). From this 
sequence the Toll gene product was found to be a transmembrane receptor with a cytoplasmic 
domain similar to interleukin-1 receptor with a large ectodomain of leucine rich repeats. Later a 
human analog of the Toll gene was discovered suggesting an evolutionarily conserved defense 
mechanism.  To date homolog mechanisms of Toll recognition in plants, insects, and 
vertebrates have been indentified to coordinate immune response.  
 Termed toll-like 
receptors, due to their 
homology to the original Toll 
gene, eleven toll-like receptors 
(TLRs) are recognized in 
humans and thirteen in mice (1, 
3). The TLRs are type I integral membrane glycoproteins. Ligand stimulation of different TLRs 
leads to differential patterns of signaling leading to distinct gene expression patterns, the 
innate immune response and instructing development of the antigen specific immune 
response. Figure one displays the TLRs and their classical ligands. TLRs are members of a larger 
Figure 1: TLRs and their classically recognized ligands 
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super family of interleukin-1 receptors (IL-1Rs) due to their sequence homology in the 
cytoplasmic region. Specifically TLRs and other IL-1R members share the Toll/IL-1R domain 
(TIR), a region of approximately 200 amino acids in the receptors cytoplasmic region. However 
the extracellular domains vary greatly in that TLRs contain a leucine rich repeat (LRR) sequence 
motif in contrast to IL-1Rs immunoglobulin domain. The number of LRR motifs varies but the 
24-29 amino acid sequence motif XXLXLXX is well conserved amongst TLRs and it is believed 
they are involved in ligand recognition.  
 Toll-Like receptor 4 (TLR4) is best known for its response to lipopolysaccharide (LPS), a 
large molecule consisting of a lipid and a polysaccharide joined by a covalent bond. LPS is found 
in the outer membrane of Gram-negative bacteria and act as endotoxins. Specifically the 
phosphorylated diglucosamine head group (lipid A) portion it required to propagate LPS-
induced TLR4 signaling. TLR4 is unique in that it requires an accessory protein, Myeloid 
differentiation factor 2 (MD-2), a secreted glycoprotein of 160 amino acids. Upon LPS binding 
the TLR4/MD-2 complex recruits another TLR4/MD-2 pair to form a homodimeric complex. This 
in turn sends a signal through TLR4s intracellular TIR domain through an unknown mechanism. 
However it is known that the heteromeric assembly of TLR4s TIR is the first step in the signal 
transduction (4).  After stimulation the signal diverges following one of two signaling cascades, 
the MyD88 pathway to nuclear factor kappa-B (NF-κB) or the toll/IL-1 receptor-containing 
adaptor inducing IFN-β (TRIF) pathway also known as the MyD88 independent pathway. All 
TLRs signal solely through the MyD88 cascade except TLR4 and TLR3. Interestingly TLR4 can 
signal through both MyD88 and the TRIF pathways whereas TLR3 signals solely through the TRIF 
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Figure 2: TLR4 Signaling Cascade (2) 
cascade. When TLR4 signals through MyD88 or TRIF is a topic of debate/research.  Figure two 
shows the TLR4 signaling cascade.  
 Current research shows that pathological 
pain invokes an inflammatory response in the 
central nervous system. In 1998 it was reported 
that pain cost the United States nearly 100 
billion doll ars per year in lost wages, lost 
productivity, and medical expenses (3).  Previous 
pain management therapies revolved around 
targeting neuronal cells; however this was 
met with only modest success. Recently glia have emerged as vital contributors to chronic pain 
mechanisms (5). Microglia comprise roughly 12% of the cells in the brain and spinal cord, thus 
their involvement in pain management does not come as a surprise (6). Of even greater interest 
is the fact that TLR4 is primarily expressed on primary microglia. Recently it has been 
discovered by the Watkins lab that opioids cause glial activation through the TLR4 pathway and 
that this activation in turn suppresses the analgesia of opioids on neurons through the release 
of cytokine intercellular mediators such as IL-1 (IL-1β and IL-1α). This glial activation can be 
linked to both opioid tolerance and dependence clinically.  
 Opioid induced glial activation early on was thought to be due to the presence of the µ-, 
δ, κ-opioid receptors in which mRNA for these receptors were detected. However recent 
literature suggests opioid induced activation may occur through another distinct avenue, TLR4.  
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Figure 3: Hypothesis of small molecule perturbation of opioid induced 
TLR4 glial activation on pain analgesia. 
Traditional opioid receptors are stereoselective binding the natural (-)-opioid isomer but does 
not recognize the unnatural (+)-opioid isomer. (+)-Opioid isomers are not only not recognized 
by traditional opioid receptors but somehow mysteriously suppress the analgesic effect of the 
(-)-opioid isomer. This effect is shown to be a result of (+)-opioids causing glial activation. In 
addition, LPS has been found to reduce morphine analgesia in vivo and upon the addition of (+)-
opioid antagonist no suppression of analgesia is shown suggesting LPS and (+)-opioids work 
through a similar mechanism (7, 8). Quite possibly TLR4 plays a vital role in this opioid induced 
glial activation (9).   
 If opioids do in fact lead to glial activation 
and in turn a suppression of opioid induced 
analgesia creating a way to selectively stop opioid 
induced TLR4 glial activation is of great interest. 
Due to glial cells residing in the CNS, blood brain 
barrier permeability is of concern if potential 
therapeutics are going to be developed. Thusly 
through the development of “Drug-Like” small 
molecules that selectively disrupt TLR4 induced 
glial activation and thereby enhance 
morphine analgesia in addition to 
reducing tolerance and dependence on these opioids is of great interest. Figure 3 displays the 
hypothesis of our work.  
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Figure 4:  Secreted embryonic Alkaline Phosphatase assay diagram. 
 
 
Research/Results: 
 In order to indentify several hit compounds with an increased probability of being able 
to perturb opioid-induced TLR4 glial activation, we turned to virtual high-throughput screening. 
ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) in silico screening was 
performed using the high resolution structure of the TLR4 extracellular domain, pdb id 2z62 
(1.70 Å resolution). Using molecular dynamics runs several conformations were chosen that 
best represented the active site of the protein. This confined protein structure was docked 
against the entire ENAMINE library of compounds consisting of around 700,000 on shelf 
compounds using the drug discovery suite from QUANTUM pharmaceuticals. As a result of the 
screening, compounds were ranked based on predicted binding energies within the active site 
of TLR4. This led to the identification of eleven “hit” 
inhibitors of the TLR4/MD-2 interaction.  
 To separate the “hit” compounds from 
potential “Lead” compounds a robust assay to 
evaluate the TLR4/MD-2 inhibitors was developed, a 
secreted embryonic alkaline phosphatase (SEAP) 
reporter assay. Human embryonic kidney-293 (HEK 
293) cells stably transfected to over 
express TLR4 along with a SEAP gene 
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located downstream of the NF-κB promoter (12). Figure four displays a schematic of the assay.  
This system allowed us to test our small molecules against LPS induced TLR4 activation. The 
results from this assay led to indentifying two possible “Lead” compounds, 4019 and 2126. The 
structure of the two “lead” compounds can been seen in figure five along with the SEAP assay 
results of compound 2126. This assay clearly shows that 2126 is able to inhibit LPS-induced 
TLR4 SEAP production in HEK 293 cells. Further testing showed 4019 was not inhibiting TLR4 
activation, and thusly was abandoned.  
 To ensure the effect of the “Lead” compounds was not just a novelty of the SEAP assay, 
RAW 264.7 murine macrophage cells which endogenously express TLR4 were used to measure 
LPS-induced nitric oxide production. Upon TLR4 activation via LPS the NF-κB promoter 
activation leads to the transcription of the iNOS gene, an inducible nitric oxide Synthase. 
Depending on the magnitude of the TLR4 activation differential nitric oxide (NO) levels in the 
media can be assessed. This assessment is done through the incubation of NO containing media 
with 2, 3-Diaminonapthalene creating a ring closure in which the absorbance can be red.  
Thusly cells treated with LPS and our lead 
compounds should show decreased nitric oxide 
production compared to a LPS only control. This 
Assay showed 2126 not 4019 was able to knock 
down LPS induced TLR4 nitric oxide production.  
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Figure 5: 2126 LPS-induced SEAP results (top right), Structure of 2126 (Left), structure of 4019 (right). 
7 
 
 Since all of the TLRs show a good amount of sequence homology the next logical step 
was to assess whether the lead compound, 2126, was selective for TLR4.  This assay simply used 
the same platform as the RAW 264.7 nitric oxide production since all of the TLRs are 
endogenously expressed within the cell and their activation ultimately leads to the production 
of iNOS and nitric oxide. Thus cells can be treated with TLR specific ligands and the compounds 
can be tested against the activation to assess the drugs TLR specificity. The ligands used were 
LPS(TLR4), poly(I:C) (polyinosinic-polycytidylic acid)(TLR3), FSL-1[(S,R)-(2,3-
bispalmitoyloxypropyl)-Cys-Gly-Asp-Pro-Lys-His-Pro-Lys-Ser-Phe]( TLR2/6), Pam3CSK4 {N-
palmitoyl-S-[2,3-bis(palmitoyloxy)-(2R,S)-propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-
lysyl-[S]-lysine 3 3HCl} (TLR1/2), and R848 {4-amino-2-(ethoxymethyl)-R,R-dimethyl-1H-
imidazo[4,5-c]quinoline-1-ethanol} (TLR7).  As seen in figure 6 compound 2126 was able to 
selectively inhibit TLR4 induced NO production in RAW 264.7 cells. 
  
 
 With 2126 shown to knockdown TLR4 activation selectively in these systems the next 
step was to attempt to enhance the potency of 2126 by creating a series of chemical 
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Figure 6: TLR specificity RAW 264.7 NO production assay 
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derivatives. In addition this would shed light on the functional groups vital for activity. A former 
graduate student in our lab, Doug Bevan, created numerous analogs of 2126 using some 
interesting chemistry. All analogs had a substitution on one of the benzene rings or both. All 
2126 derivatives were screened using the SEAP reporter gene assay as described previously. 
Table one shows substitutions made and the percent of SEAP gene activation inhibition at a 
concentration of 50µM of drug measured (11). Most compounds showed modest inhibition at 
best, except for the dually chlorinated compound 15, in which 99% inhibition was shown. 
Compared to our original “Lead” compound 1 (2126). 
                        
Table 1: Result of the SEAP Reporter Gene Activation Assay 
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Figure 7: RAW 264.7 Nitric Oxide selectivity data. All ligands 
tested at a drug concentration of 25 µM. 
 The 2126 analog showed promise in 
the SEAP assay, however it was important 
to once again show that it was indeed 
specific for TLR4 and worked in the NO 
production assay. As before with the 
original compound it was able to 
selectively inhibit the LPS-induced NO production and not that of the other TLR ligands (11).  
Figure 7 shows the RAW NO selectivity data.   
 Although these tests were able to show that our compound was able to selectively 
inhibit the end result of LPS-induced TLR4 signaling, it was important to test the compounds in 
animals to see if they could in fact potentiate the actions of morphine. Linda Watkins our 
collaborator graciously agreed to test the compounds in conjunction with morphine using their 
well established rat model. The Hargreaves test was used to assess the time taken for an 
unrestrained rat to show a heat-induced pain withdraw response, a tail flick (11). Baseline 
readings are taken prior to drug administration, and then drugs are injected intrathecally and 
Hargreaves tail flick response measured over a three hour time course. Rat studies performed 
on both 2126 and its analog compound 15 showed the ability to potentiate the action of acute 
morphine analgesia. In addition to showing no analgesic effect when not co administered with 
morphine, a response similar to the PBS vehicle control. Compounds, 2126 and 2126 analog 15, 
showed modest potency in vivo EC50= 48.1±2.1 µM and EC50= 18.7±3.2 µM, respectively (11).  
For brevity, only the rat data for 2126 analog 15 is shown in figure 8 (11). 
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 With 2126 and 2126 analog 15 established to potentiate the actions of morphine in vivo 
it was important to further test our cellular work. In order to create a model system closer to 
our hypothesis that our small molecule can inhibit morphine-induced TLR4 activation and 
release of IL-1, BV-2 murine microglia cells were obtained from the Watkins lab. An Enzyme 
linked Immunosorbent Assay (ELISA) against IL-1β was performed. Upon morphine treatment 
there should be arise in cellular IL-1β levels that can be detected through ELISA and compared 
to a media control. Recent data has shown that with the use of (+)-dihydromorphine we can 
create a robust IL-β response in the BV-2 microglia system, LPS was used as a positive control. 
Figure 9 shows the most recent BV-2 ELISA data showing robust IL-1β activation upon (+)-
dihydromorphine treatment and the structure of dihydromorphine. Now that the assay has 
been established in our lab we hope to test 2126 analog 15 against morphine induced BV-2 IL-
1β production. Prior to our optimization of the assay, Dr. Lisa Loram established the same 
system and graciously tested our original “Lead” 2126. Results showed the ability of 2126 to 
decrease the amount of IL-1β produced from morphine induced glial activation.                   
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Conclusion: 
 Our work over the past year has provided intriguing insights into the function of our 
small molecule TLR4 activation inhibitors. Initial studies show the ability of our “Lead” 
compound to knockdown TLR4 activation, Potentiate morphine analgesia in rat models, and 
decrease IL-1β release upon morphine induced activation. Although our work is promising, 
there is still further need to prove our small molecule does in fact act on TLR4. Future work will 
revolve around biophysical binding assay to prove the small molecule can disrupt the TLR4/MD-
2 interaction. Co-IP will be performed with HIS-FLAG tagged MD-2 and FLAG-tagged TLR4 using 
a nickel column. In theory our small molecules should disrupt the TLR4/MD-2 interaction and 
decrease the amount of TLR4 co-immunopercipitated with MD-2. The work completed to date 
shows an exciting potential to potentiate the actions of opioids in hopes of dealing with the 
negative effects associated with opioid treatment.  
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